The Europe enteral nutrition market size is projected to reach US$ 5,797.18 million by 2031 from US$ 3,322.95 million in 2023. The market is expected to register a CAGR of 7.2% during 2023–2031. Standardized formulations and plant-based nutrition products are likely to bring in new market trends during the forecast period.
Gastrointestinal diseases include Crohn's disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and certain cancer types. These diseases often lead to malabsorption of nutrients due to inflammation, damage, or dysfunction of the intestines. Crohn's disease is a complex, chronic disorder primarily affecting the digestive system. Research conducted by Crohn's & Colitis UK shows that ~1 in every 123 people in the UK had either Crohn's disease or ulcerative colitis in 2022, accounting for nearly 0.5 million people living with IBD in the UK. According to the study "Tackling the Burden of Digestive Disorders in Europe" published in 2023, over 332 million people are estimated to be living with a digestive disorder in European countries. As per the study, digestive cancers accounted for one-third of the total number of cancer-related deaths among the countries surveyed.
The Europe enteral nutrition market is rapidly expanding with the increasing aging population; rise in chronic diseases such as cancer, diabetes, and neurological disorders (viz., stroke and dementia); and surging awareness of the benefits of enteral nutrition, supported by clinical guidelines. Technological innovations and a growing focus on personalized care are expected to favor the growth of the market in the future.
Undernutrition, overweight or obesity, vitamin or mineral deficiency, and poor diet-related noncommunicable diseases are all categorized under malnutrition. The European Society for Clinical Nutrition and Metabolism (ESPEN) and the World Health Organization (WHO) conducted a joint 46th ESPEN Congress in Milan, Italy, in September 2024. The Congress reported that malnutrition affects 30–50% of hospitalized patients, 40% of oncology patients, 30–70% of older adults, 24% of hospitalized cardiovascular or pulmonary disease patients, and 38–78% of patients in intensive care units in Europe. Similarly, as per the "A Multi-Center Survey on Hospital Malnutrition," published in 2021, nearly 11–45% of patients in hospitals and home care settings in England suffered from malnutrition. Nutritional support can be delivered through enteral means, depending on the need, which is an essential and appropriate way of treating most malnutrition cases. Thus, the massive burden of malnutrition in patients from different age groups and the increasing number of premature births drive the demand for enteral nutrition formulae and products in Europe.
Companies operating in the Europe enteral nutrition market continuously focus on strategic developments such as collaborations, expansions, agreements, partnerships, and innovative product formulations. These strategies help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the enteral nutrition market are mentioned below.
• In May 2024, Danone completed the acquisition of Functional Formularies, a leading whole-food tube feeding business in the US. Through this acquisition, Danone has plans to strengthen its Medical Nutrition portfolio in the US by further expanding its enteral tube feeding ranges.
• In January 2023, Nutricia launched Fortimel PlantBased Energy, its first plant-based, ready-to-drink oral nutritional supplement. The product is specifically formulated to fulfill the nutritional needs of malnourished populations or people at risk of malnutrition due to illness. Following the launch of Fortimel, the company plans to leverage Danone's (parent company) expertise in plant nutrition to expand its Fortimel portfolio. The new product is available in the Netherlands, Denmark, Norway, Spain, Finland, and the Czech Republic.
Key segment that contributed to the derivation of the Europe enteral nutrition market analysis is product type.
The Europe enteral nutrition market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Germany and France together are expected to account for a significant market share during the forecast period. Further, Italy, the UK, and Spain are likely to present lucrative opportunities for the market in the coming years. Market growth in Europe is mainly attributed to the increasing geriatric population, rising incidence of chronic diseases and neurological disorders such as stroke and cerebral aneurysms, and product innovations by players operating in the region.
The regional trends and factors influencing the Europe Enteral Nutrition Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Europe Enteral Nutrition Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 3,322.95 Million |
| Market Size by 2031 | US$ 5,797.18 Million |
| Global CAGR (2023 - 2031) | 7.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The Europe Enteral Nutrition Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Europe Enteral Nutrition Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Europe enteral nutrition market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Below is a key development witnessed in the Europe enteral nutrition market:
The "Europe Enteral Nutrition Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
Germany dominated the market in 2023.
An increase in the prevalence of chronic disease and a surge in elderly populations are among the significant factors fueling the market growth.
Standardized formulations and plant-based nutrition products are likely to emerge as new growth trends in the market in the coming years.
The Europe enteral nutrition market value is expected to reach US$ 5,797.18 million by 2031.
Nestle SA, Danone SA, Abbott, Fresenius SE & Co KGaA, and B Braun are among the key players operating in the market.
The market is expected to register a CAGR of 7.2% during 2023–2031.